|
1
|
Pliarchopoulou K and Pectasides D:
Pancreatic cancer: current and future treatment strategies. Cancer
Treat Rev. 35:431–436. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ramon Torrell JM and Serra Majem L:
Descriptive epidemiology of cancer of the stomach in Catalonia
1983–1986. Gac Sanit. 4:76–77. 1990.(In Spanish).
|
|
3
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
4
|
Bardeesy N and DePinho RA: Pancreatic
cancer biology and genetics. Nat Rev Cancer. 2:897–909. 2002.
View Article : Google Scholar
|
|
5
|
Michalik L, Auwerx J, Berger JP, et al;
International Union of Pharmacology. LXI Peroxisome
proliferator-activated receptors. Pharmacol Rev. 58:726–741. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kersten S, Desvergne B and Wahli W: Roles
of PPARs in health and disease. Nature. 405:421–424. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhu YJ, Crawford SE, Stellmach V, et al:
Coactivator PRIP, the peroxisome proliferator-activated
receptor-interacting protein, is a modulator of placental, cardiac,
hepatic, and embryonic development. J Biol Chem. 278:1986–1990.
2003. View Article : Google Scholar
|
|
8
|
Lemberger T, Desvergne B and Wahli W:
Peroxisome proliferator-activated receptors: a nuclear receptor
signaling pathway in lipid physiology. Annu Rev Cell Dev Biol.
12:335–363. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Auboeuf D, Rieusset J, Fajas L, et al:
Tissue distribution and quantification of the expression of mRNAs
of peroxisome proliferator-activated receptors and liver X
receptor-alpha in humans: no alteration in adipose tissue of obese
and NIDDM patients. Diabetes. 46:1319–1327. 1997. View Article : Google Scholar
|
|
10
|
Kliewer SA, Forman BM, Blumberg B, et al:
Differential expression and activation of a family of murine
peroxisome proliferator-activated receptors. Proc Natl Acad Sci
USA. 91:7355–7359. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bishop-Bailey D and Hla T: Endothelial
cell apoptosis induced by the peroxisome proliferator-activated
receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2. J
Biol Chem. 274:17042–17048. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xin X, Yang S, Kowalski J and Gerritsen
ME: Peroxisome proliferator-activated receptor gamma ligands are
potent inhibitors of angiogenesis in vitro and in vivo. J Biol
Chem. 274:9116–9121. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Marcus SL, Miyata KS, Zhang B, Subramani
S, Rachubinski RA and Capone JP: Diverse peroxisome
proliferator-activated receptors bind to the peroxisome
proliferator-responsive elements of the rat hydratase/dehydrogenase
and fatty acyl-CoA oxidase genes but differentially induce
expression. Proc Natl Acad Sci USA. 90:5723–5727. 1993. View Article : Google Scholar
|
|
14
|
Kliewer SA, Umesono K, Mangelsdorf DJ and
Evans RM: Retinoid X receptor interacts with nuclear receptors in
retinoic acid, thyroid hormone and vitamin D3 signalling. Nature.
355:446–449. 1992. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ramachandran L, Manu KA, Shanmugam MK, et
al: Isorhamnetin inhibits proliferation and invasion and induces
apoptosis through the modulation of peroxisome
proliferator-activated receptor gamma activation pathway in gastric
cancer. J Biol Chem. 287:38028–38040. 2012. View Article : Google Scholar
|
|
16
|
Bishop-Bailey D: PPARs and angiogenesis.
Biochem Soc Trans. 39:1601–1605. 2011. View Article : Google Scholar
|
|
17
|
Jung UJ, Torrejon C, Chang CL, Hamai H,
Worgall TS and Deckelbaum RJ: Fatty acids regulate endothelial
lipase and inflammatory markers in macrophages and in mouse aorta:
a role for PPARgamma. Arterioscler Thromb Vasc Biol. 32:2929–2937.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tontonoz P, Hu E and Spiegelman BM:
Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a
lipid-activated transcription factor. Cell. 79:1147–1156. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gelman L, Fruchart JC and Auwerx J: An
update on the mechanisms of action of the peroxisome
proliferator-activated receptors (PPARs) and their roles in
inflammation and cancer. Cell Mol Life Sci. 55:932–943. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fajas L, Debril MB and Auwerx J:
Peroxisome proliferator-activated receptor-gamma: from adipogenesis
to carcinogenesis. J Mol Endocrinol. 27:1–9. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang T, Xu J, Yu X, Yang R and Han ZC:
Peroxisome proliferator-activated receptor gamma in malignant
diseases. Crit Rev Oncol Hematol. 58:1–14. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kristiansen G, Jacob J, Buckendahl AC, et
al: Peroxisome proliferator-activated receptor gamma is highly
expressed in pancreatic cancer and is associated with shorter
overall survival times. Clin Cancer Res. 12:6444–6451. 2006.
View Article : Google Scholar
|
|
23
|
Watkins G, Douglas-Jones A, Mansel RE and
Jiang WG: The localisation and reduction of nuclear staining of
PPARgamma and PGC-1 in human breast cancer. Oncol Rep. 12:483–488.
2004.PubMed/NCBI
|
|
24
|
Segawa Y, Yoshimura R, Hase T, et al:
Expression of peroxisome proliferator-activated receptor (PPAR) in
human prostate cancer. Prostate. 51:108–116. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Theocharis S, Kanelli H, Politi E, et al:
Expression of peroxisome proliferator activated receptor-gamma in
non-small cell lung carcinoma: correlation with histological type
and grade. Lung Cancer. 36:249–255. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang GY, Ahmed N, Riley C, et al:
Enhanced expression of peroxisome proliferator-activated receptor
gamma in epithelial ovarian carcinoma. Br J Cancer. 92:113–119.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sasaki T, Fujimoto Y, Tsuchida A, Kawasaki
Y, Kuwada Y and Chayama K: Activation of peroxisome
proliferator-activated receptor gamma inhibits the growth of human
pancreatic cancer. Pathobiology. 69:258–265. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hahn WC, Dessain SK, Brooks MW, et al:
Enumeration of the simian virus 40 early region elements necessary
for human cell transformation. Mol Cell Biol. 22:2111–2123. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Soumaoro LT, Uetake H, Higuchi T, Takagi
Y, Enomoto M and Sugihara K: Cyclooxygenase-2 expression: a
significant prognostic indicator for patients with colorectal
cancer. Clin Cancer Res. 10:8465–8471. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Asou H, Verbeek W, Williamson E, et al:
Growth inhibition of myeloid leukemia cells by troglitazone, a
ligand for peroxisome proliferator activated receptor gamma, and
retinoids. Int J Oncol. 15:1027–1031. 1999.PubMed/NCBI
|
|
31
|
Zang C, Liu H, Posch MG, et al: Peroxisome
proliferator-activated receptor gamma ligands induce growth
inhibition and apoptosis of human B lymphocytic leukemia. Leuk Res.
28:387–397. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sato H, Ishihara S, Kawashima K, et al:
Expression of peroxisome proliferator-activated receptor
(PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma
agonists. Br J Cancer. 83:1394–1400. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sarraf P, Mueller E, Smith WM, et al:
Loss-of-function mutations in PPAR gamma associated with human
colon cancer. Mol Cell. 3:799–804. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mueller E, Sarraf P, Tontonoz P, et al:
Terminal differentiation of human breast cancer through PPAR gamma.
Mol Cell. 1:465–470. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ogino S, Shima K, Baba Y, et al:
Colorectal cancer expression of peroxisome proliferator-activated
receptor gamma (PPARG, PPARgamma) is associated with good
prognosis. Gastroenterology. 136:1242–1250. 2009. View Article : Google Scholar
|
|
36
|
Inoue K, Kawahito Y, Tsubouchi Y, et al:
Expression of peroxisome proliferator-activated receptor gamma in
renal cell carcinoma and growth inhibition by its agonists. Biochem
Biophys Res Commun. 287:727–732. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Eibl G, Wente MN, Reber HA and Hines OJ:
Peroxisome proliferator-activated receptor gamma induces pancreatic
cancer cell apoptosis. Biochem Biophys Res Commun. 287:522–529.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Farrow B and Evers BM: Activation of
PPARgamma increases PTEN expression in pancreatic cancer cells.
Biochem Biophys Res Commun. 301:50–53. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Itami A, Watanabe G, Shimada Y, et al:
Ligands for peroxisome proliferator-activated receptor gamma
inhibit growth of pancreatic cancers both in vitro and in vivo. Int
J Cancer. 94:370–376. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Katz MH, Fleming JB, Lee JE and Pisters
PW: Current status of adjuvant therapy for pancreatic cancer.
Oncologist. 15:1205–1213. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Squadroni M and Fazio N: Chemotherapy in
pancreatic adenocarcinoma. Eur Rev Med Pharmacol Sci. 14:386–394.
2010.PubMed/NCBI
|
|
42
|
Duxbury MS, Ito H, Zinner MJ, Ashley SW
and Whang EE: Inhibition of SRC tyrosine kinase impairs inherent
and acquired gemcitabine resistance in human pancreatic
adenocarcinoma cells. Clin Cancer Res. 10:2307–2318. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Leung L, Radulovich N, Zhu CQ, et al:
Lipocalin2 promotes invasion, tumorigenicity and gemcitabine
resistance in pancreatic ductal adenocarcinoma. PLoS One.
7:e466772012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Awasthi N, Zhang C, Ruan W, Schwarz MA and
Schwarz RE: BMS-754807, a small-molecule inhibitor of insulin-like
growth factor-1 receptor/insulin receptor, enhances gemcitabine
response in pancreatic cancer. Mol Cancer Ther. 11:2644–2653. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang H, Pei W, Luan Q, et al: A
feasibility study on gene therapy of pancreatic carcinoma with
Ad-PUMA. Cancer Biol Ther. 13:712–719. 2012. View Article : Google Scholar : PubMed/NCBI
|
